You will only receive an alert if new information was published since you received one.
Many environmental factors can influence cancer incidence. Genes also play a role. However, the causes of many types of cancer are still unknown.
Indicators for Non-Communicable Diseases (NCD)
The indicator describes the following: cancer incidence, by type of cancer, per 100 000 person years.
The indicator describes the following: Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics (in grams of morphine) per death from cancer.
The purpose of this systematic review was to evaluate the effect of three screening strategies for women below 34 years.
Health technology assessment
The Norwegian Institute of Public Health was commissioned to evaluate molecular tests for the identification of somatic PIK3CA mutations in men and postmenopausal women with HR+/HER2–, advanced or met...
The Norwegian Institute of Public Health has been commissioned to assess molecular tests for the identification of NTRK gene fusions in locally advanced or metastatic solid tumours.
The Norwegian Institute of Public Health has been commissioned to evaluate molecular tests for the identification of somatic ROS1 gene alterations in people with locally advanced or metastatic non-sma...
The Ordering Forum (Bestillerforum for nye metoder) commissioned the Norwegian Institute of Public Health to evaluate commercial PD-L1 tests for use in treatment of urothelial carcinoma.
This report seeks to explore the interface between personalized medicine and public health.
We were commissioned to perform a health technology assessment of SpaceOAR™ hydrogel for prevention of radiation-induced side effects following treatment for prostate cancer.
We were asked to find and summarize key findings from systematic reviews about the effectiveness of active observation treatment compared to surgery for patients with pancreatic cancer.
We aimed to summarise findings about the effectiveness of androgen suppression therapy, chemotherapy, radiation and radioactive treatment in addition to standard care for metastatic prostate cancer.